Model-Informed Precision Dosing of Imipenem in an Obese Adolescent Patient with Augmented Renal Clearance and History of Schizophrenia
Yueliang Chen,Yun Han,Feng Guo,Zhenwei Yu
DOI: https://doi.org/10.2147/idr.s450294
2024-02-28
Infection and Drug Resistance
Abstract:Yueliang Chen, 1, &ast Yun Han, 2, 3, &ast Feng Guo, 1 Zhenwei Yu 2, 3 1 Intensive Care Unit, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China; 2 Department of Pharmacy, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China; 3 Research Center for Clinical Pharmacy, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China &astThese authors contributed equally to this work Correspondence: Feng Guo; Zhenwei Yu, Email ; Imipenem is a broad-spectrum antibiotic that has been used in treating severe infections and exhibits a time-dependent PK/PD profile. Its dose should be adjusted based on renal function. However, there is little experience with imipenem dosing in obese adolescent patients with augmented renal clearance (ARC) and history of schizophrenia. This case reported successful dosing of imipenem in an obese a dolescent patient with ARC based on therapeutic drug monitoring (TDM) and model-informed precision dosing (MIPD). A 15-year-old male adolescent patient with history of schizophrenia was diagnosed with ventilator-associated pneumonia due to carbapenem-susceptible Klebsiella pneumoniae and received imipenem treatment (0.5 g every 8 hours with a 1-hour infusion). However, the exposure of imipenem was suboptimal due to ARC, and there is no available model for MIPD in this patient. Thus, we utilized prediction error to find a population pharmacokinetic model that fit this patient and ran Maximum a posteriori Bayesian estimation and Monte Carlo simulation based on screened models to predict changes in drug concentrations. The dose of imipenem was adjusted to 0.5 g every 6 hours with a 2-hour infusion, and subsequent TDM revealed that dosing adjustment was accurate and successful. Finally, the patient's status of infection improved. This study will be beneficial to imipenem dosing in similar cases in the future, thereby improving the safety and effectiveness of imipenem or other antibiotics. Keywords: case report, imipenem, therapeutic drug monitoring, population pharmacokinetic Imipenem is a broad-spectrum and highly effective antibiotic that can treat severe infections with advantages. 1,2 Imipenem is also a time-dependent antibiotic, and the pharmacokinetic pharmacodynamic (PK/PD) index that is related to its efficacy is the fraction of time that the free drug concentration remains above the minimum inhibitory concentration (MIC) during a dosing interval (% f T>MIC). 3,4 It is mainly eliminated through the kidney, and the dose should be adjusted based on renal clearance. Augmented renal clearance (ARC) is measured as urinary clearance ≥130 mL∙min −1 ∙1.73 m −2 in adults. 5 Some studies have continued to use adult standards for pediatric patients, 6,7 while others have defined ARC for pediatric patients as eGFR above media value (≥160 mL∙min −1 ∙1.73 m −2 ) through logistic regression analysis. 8,9 In a study on the vancomycin in children with ARC, the subtherapeutic cutoff value of eGFR was set to 110.51 mL∙min −1 ∙1.73 m −2 . 10 ARC is common in intensive care unit (ICU) patients, while trauma, young age, male sex, admission with central nervous system disease, use of mechanical ventilation, and use of vasopressor were independent risk factors for ARC. 11,12 These patients may have insufficient drugs exposure due to excessive elimination. Adolescent critically ill patients with ARC and history of schizophrenia were not clinically typical, and there were few case reports of imipenem dose adjustment in these patients. 13 Model-informed precise dosing (MIPD) is proven to be better in PK/PD target attainment than empiric dosing when prescribing antibiotics. 14 However, there are also few model data about the PK of imipenem in ARC patients, especially adolescents. 15 We herein report on an exceptional adolescent critically ill patient with ARC and obesity who used therapeutic drug monitoring (TDM) and the MIPD method to achieve optimal imipenem exposure. A 15-year-old male pediatric patient was admitted to the intensive care unit (ICU) because of his severe acute pancreatitis and secondary respiratory failure. Although the patient was 15 years old, he had obesity with a weight of 87 kg and height of 177 cm. He had a previous history of schizophrenia over 3 years and fatty liver and sinusitis over 1 year. He was treated with olanzapine 20 mg daily and clozapine 50 mg daily before admission. Because of persistent pain in the upper abdomen and vomiting, he went -Abstract Truncated-
pharmacology & pharmacy,infectious diseases